Pyruvate Kinase M2 Mutations in Human Cancers: Effects on Enzyme Function



William J. Israelsen, Vivian M. Liu, Aaron M. Hosios, Matthew G. Vander Heiden

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

ABSTRACT

Human_M2 Human_M1 Human_R Human_L


Mouse_M1 Mouse_M2

Fructose-1,6-Bisphosphate


Cancer cells must regulate metabolic fluxes to meet both anabolic and catabolic needs. An important point of metabolic regulation is the final step in glycolysis, which is catalyzed in cancer cells by the M2 isoform of pyruvate kinase (PKM2). Mutations in PKM2 arising in human cancers are of special interest because the functional effects of these mutations may provide insight into the selective pressures placed on the regulation of metabolism in human tumors. We therefore sought to characterize the effects of PKM2 mutations from patient tumor samples on the metabolic function of the enzyme. The majority of identified PKM2 mutations were point mutations resulting in changes to highly conserved amino acids, with 13 of 26 mutations occurring in residues that are perfectly conserved from humans to S. cerevisiae. Kinetic characterization of mutant enzymes showed that the mutations generally reduce enzymatic activity by lowering Vmax, increasing Km for substrate (phosphoenolpyruvate), or both. Some amino acid substitutions also reduce binding affinity for the allosteric activator fructose-1,6-bisphosphate (FBP) or completely abolish activation by FBP. These results suggest that tumor growth conditions in vivo tolerate or select for reduced PKM2 activity.

FIGURE 1 **PKM2 Mutations Occur in Human Cancers**


A. Missense Mutations Cause Truncations And Substitutions







B. Amino Acid Substitutions Occur in Highly Conserved Residues



C. Locations of Select Amino Acid Substitutions are Highlighted in Blue **Kinetics for Numbered Mutants Are Shown in Figure 3.**






FIGURE 2 PKM2 Copurifies with Bound Fructose-1,6-Bisphosphate (FBP), an Allosteric Activator A. Single-step IMAC Purification Does Not Remove FBP B. FBP Activation Can Be Observed After Refolding Without FBP or When Assaying Non-Tetramer Fraction **Dimer Can Be Activated by FBP** • 0 mM FBP





CONCLUSIONS

- Point Mutations in PKM2 Have Been Found in Human Tumors
- Cancer-Associated Amino Acid Substitutions Affect PKM2 Enzymatic Function
- PEP-Dependent Protein Phosphorylation Requires the Presence of ADP

ACKNOWLEDGEMENTS

Funding was provided by the NIH and the Smith Family Foundation.